Topics

FDA Grants Breakthrough Therapy Designation to PhaseBio’s PB2452 for the Reversal of Antiplatelet Activity of Ticagrelor

14:25 EDT 9 Apr 2019 | Speciality Pharma Journal

MALVERN, Pa. and SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the …

Original Article: FDA Grants Breakthrough Therapy Designation to PhaseBio’s PB2452 for the Reversal of Antiplatelet Activity of Ticagrelor

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to PhaseBio’s PB2452 for the Reversal of Antiplatelet Activity of Ticagrelor"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...